Pasithea Therapeutics warrants delisted from Nasdaq

Pasithea Therapeutics Corp. (KTTA) reports that its warrants are being removed from listing and/or registration on the Nasdaq Stock Market LLC through a Form 25 filing under Section 12(b) of the Securities Exchange Act of 1934.

Rhea-AI Filing Summary

Pasithea Therapeutics Corp. (KTTA) reports that its warrants are being removed from listing and/or registration on the Nasdaq Stock Market LLC through a Form 25 filing under Section 12(b) of the Securities Exchange Act of 1934.

Nasdaq states it has complied with its rules to strike this class of securities, and Pasithea is reported to have complied with the exchange’s rules and 17 CFR 240.12d2-2(c) governing voluntary withdrawal from listing and registration.

Filing Explained

The filing records Nasdaq’s notification to strike Pasithea Therapeutics’ warrants from listing and withdraw their Section 12(b) registration. Its disclosed state is a removal notification, not a statement that the delisting and deregistration are already effective.

Key Terms

Form 25, Section 12(b) of the Securities Exchange Act of 1934, 17 CFR 240.12d2-2(b), 17 CFR 240.12d2-2(c), +1 more

5 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) of the Securities Exchange Act of 1934 regulatory

"REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES"

17 CFR 240.12d2-2(b) regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules"

17 CFR 240.12d2-2(c) regulatory

"requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal"

voluntary withdrawal regulatory

"governing the voluntary withdrawal of the class of securities from listing"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Pasithea Therapeutics Corp. (KTTA) disclose in this Form 25 filing?

The filing reports that warrants of Pasithea Therapeutics Corp. are being removed from listing and/or registration on the Nasdaq Stock Market LLC through a Form 25 submitted under Section 12(b) of the Securities Exchange Act of 1934.

Which Pasithea Therapeutics (KTTA) security is affected by this Form 25?

The Form 25 covers Pasithea Therapeutics Corp. warrants. It describes the removal of this class of securities from listing and/or registration on the Nasdaq Stock Market LLC pursuant to the procedures in 17 CFR 240.12d2-2.

What role does Nasdaq play in KTTA’s warrant delisting?

Nasdaq Stock Market LLC certifies that it has complied with its rules to strike the class of Pasithea Therapeutics Corp. warrants from listing and/or withdraw their registration, as provided under 17 CFR 240.12d2-2(b).

How has Pasithea Therapeutics (KTTA) participated in the warrant delisting process?

Pasithea Therapeutics Corp. is stated to have complied with the exchange’s rules and the requirements of 17 CFR 240.12d2-2(c), which govern the voluntary withdrawal of a class of securities from listing and registration.

Who signed the Form 25 related to KTTA’s warrants?

The notification is signed on behalf of Nasdaq Stock Market LLC by Tara Petta, identified as an AVP, as the duly authorized person for submitting the Form 25 certification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:05 PM Accepted by SEC EDGAR 09/16/2026 - 04:04 PM Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-40804

Issuer:	Pasithea Therapeutics Corp.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1111 Lincoln Road
	Suite 500
	Miami Beach	FLORIDA	33139
Telephone number:					702-514-4174

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

warrants

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-09-16	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.